Professional Documents
Culture Documents
Cv-ev-2011-Hr Prof DR SC Vrdoljak
Cv-ev-2011-Hr Prof DR SC Vrdoljak
Osobni podaci:
Državljanstvo: Hrvatsko
Radna adresa:
Naobrazba:
Postdoktorska naobrazba:
Zaposlenja:
1
.
1992 – 1995 specijalizant iz radioterapije i onkologije, Centar za Onkologiju i
Radioterapiju, Klinička Bolnica "Split".
1995 – danas specijalist onkologije i radioterapije KBC Split
1995/1996 viši asistent u kumulativnom radnom odnosu na katedri za
radiologiju i opću kliničku onkologiju Medicinskog fakulteta u
Zagrebu za potrebe nastave u Splitu
1997/1998 Docent u kumulativnom radnom odnosu na katedri za radiologiju i
opću kliničku onkologiju Medicinskog fakulteta u Zagrebu za
potrebe nastave u Splitu
2002/2003 Izvanredni profesor na katedri za radiologiju i opću kliničku
onkologiju Medicinskog fakulteta u Zagrebu za potrebe nastave u
Splitu
2007/2008 Redoviti profesor na Medicinskom fakultetu u Splitu i Mostaru
2001/2002 Gostujući profesor na Medicinskom fakultetu u Mostaru
2003 – danas Savjetnik na Klinici za onkologiju KB Mostar
2007 – danas Predsjednik Jugoistočna Europska Grupa za Istraživanja na
Području Onkologije
2008 – danas Predsjednik Hrvatskog onkološkog društva
Nagrade:
2
Aktivnosti:
3. Bill CA, Grochan BM, Vrdoljak E, Mendoza EA, Tofilon P. Decreased repair of
radiation-induced DNA double-strand breaks with cellular differentation. Rad Res
1992:132;254-258.
4. Vrdoljak E, Bill CA, Stephens LC, van der Kogel AJ, Kian Ang K, Tofilon PJ.
Radiation induced apoptosis of oligodendrocytes in vitro. Int J Radiat Biol
1992:62;4;475-480.
5. Bill CA, Mendoza E, Vrdoljak E, Tofilon PJ. Enhancment of tumor cell killing in
vitro by pre- and post-irradiation expossure to aclacinomycin A. Radiotherapy
and Oncol 1993:28;63-69.
6. Vrdoljak E, Miše K, Rozga A, Sapunar D, Marušić M. Survival analysis of
untreated patients with non-small lung cancer. Chest 1994;106:1797-81.
3
8. Vrdoljak E, Bill CA, Stepens LC, Borchardt PE, Tofilon PJ. Influence of X-rays on
early response gene expression in rat astrocytes and brain tumor cell lines. Int J
Radiat Biol. 1994:66;6:739-747.
10. Phan TP, Crane CH, Janjan NA, Vrdoljak E, Milas L, Mason KA. WR-2721
Reduces Intestinal Toxicity from Concurrent Gemcitabine and Radiation
Treatment. Int J of Pancreatol 2001;29:45-50
14. Kristensen GB. Vergote I. Stuart G. Del Campo JM. Kaern J. Lopez AB.
Eisenhauer E. Aavall-Lundquist E. Ridderheim M. Havsteen H. Mirza MR.
Scheistroen M. Vrdoljak E. First-line treatment of ovarian cancer FIGO stages
IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin.
International Journal of Gynecological Cancer. 13(Suppl 2):172-177, 2003 Nov-
Dec.
17. Čufer T, Vrdoljak E., Gaafar R, Ernesoy I, Pemberton K. Results from a phase
II, open-label, randomized study (SIGN) comparing gefitinib (iressa) with
docetaxel as second-line therapy in patients with advanced (stage IIIb or IV)
non-small-cell lung cancer. Anticancer Drugs, 2006 Apr;17(4):401-9.
4
19. Boraska Jelavić T, Barišić M, Drmić I, Boraska V, Vrdoljak E, Peruzović M, Hozo
I, Puljiz Z, Terzić J. Microsatelite GT polymorphism in the toll-like receptor 2 is
associated with colorectal cancer. Clin Genet 2006;70:156-60.
21. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cowthorn JS,
Patel A, Snowdon C, Hall E, Bliss JM, Coombes CR. Skeletal effects of
exemestane on bone-mineral density, bone biomarkers, and fracture incidence
in postmenopausal women with early breast cancer participating in the
Intergroup Exemestane Study (IES): a randomized controlled study.
HTTP://oncology.thelencet.com. Objavljeno online 26.01.2007. Lancet Oncol.
2007 Feb;8(2):119-27.
26. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A,
Bliss JM, Coombes RC, Kilburn LS. Reversal of skeletal effects of endocrine
treatments in the Intergroup Exemestan Study. Breast Cancer Res Treat 2010.
5
28. Vrdoljak E, Omrčen T, Boban M, Hrabar A. Phase II stud< of bevacizumab in
combination with capecitabine as first-line treatment in eldery patients with
metastatic colorectal cancer. Anticancer Drugs, 2011;22:191-197.
6
8. Vrdoljak E, Omrčen T, Boban M. Capecitabine and mitomycin-C in therapy of
pretreated patients with metastatic colorectal cancer: single center retrospective
study with 36 patients, J BOUN. 2008 Oct-Dec; 13(4):513-8.
1. Vrdoljak E, Bill CA, Stephens LC, Tofilon PJ. Modulation of gene expression in
astrocytes by ionizing radiation. Abstracts of Papers for the Fortieth Annual
Meeting of the Radiation Research Society; 1992:119.
2. Vrdoljak E, Bill CA, Tofilon PJ. X-ray induced early response gene expression in
rat astrocytes and brain tumor cell lines. Congress Proceedings, Tenth
International Congress of Radiation Research, 1995:223.
7
3. Bill CA, Grochan BM, Vrdoljak E, Tofilon PJ. Reduction of radiation-induced
DNA double-strand break repair with cellular differentation. Abstracts of Papaers
for the Fortieth Annual Meeting of the Radiation Research Society, 1992:75.
13. Vrdoljak E. Omrčen T, Prskalo T, Frleta Ilić N, Boban M, Petric Mise B, Boraska
Jelavić T, Šitum K, Hrepić D, Janković S, Hamm W. Konkomitantna
radiobrahiradiokemoterapija u liječenju raka vrata maternice – mogućnost
daljnjeg unapređenja liječenja. Kniga sažetaka, HDRO 2003; 26.
8
14. E. Vrdoljak, F. Grubišić Čabo. Optimalna integracija kemoterapije i hormonske
terapije u adjuvantnom liječenju raka dojke. Zbornik radova 14. Znanstvenog
sastanka o bolestima dojke. 2004; 131-138.
15. Vrdoljak E, Boraska Jelavić T. Uloga hormonske terapije u liječenju raka dojke.
Zbornik radova II Kongresa Hrvatskog onkološkog društva. 2004; 54.
16. Čufer T, Vrdoljak E. Results from a phase II, open-label, randomized study
(SIGN) comparing gefitinib with docetaxel as second line therapy in patients with
advanced (stage IIIb and IV) non-small-cell lung cancer. ASCO Annual Meeting
Proceedings 2005:7035.
17. Čufer T, Vrdoljak E. SIGN: a Phase II, open label, randomized study comparing
gefitanib (Iressa) with docetaxel as second-line therapy in patients with
advanced (stage IIIb or IV) non-small-cell lung cancer. Abstracts of the 11th
World Conference on Lung Cancer, Lung Cancer 2005;49, S87.
19. Vrdoljak E. The role of the endocrine therapy in breast cancer. European
School of Oncology, 2nd Sarajevo Breast Cancer Conference, Abstract book
2003.
21. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, Snowdon CF,
Hall E, Bliss JM, Coombes RC. Skeletal effect of exemestane in the Intergroup
Exemestane Study (IES) – 2 year bone mineral density (BMD) and bone mineral
data. Breast Cancer 2005;94:5076.
22. Vrdoljak E., Curić Z, Boraska Jelavić T, Novaković Saratlija Ž, Boban M. Uloga
aromataznih inhibitora u liječenju raka dojke – da li su svi aromatazni inhibitori
jednaki?. Zbornik radova 15. Znanstvenog sastanka o bolestima dojke. 2005;
137-157.
23. Vrdoljak E., Šitum K. Neoadjuvantno sustavno liječenje raka dojke – današnje
stanje i buduće perspektive. Zbornik radova 16. Znanstvenog sastanka o
bolestima dojke. 2006; 157-177.
25. Cufer T, Vrdoljak E. Results from a phase II, open label, randomized study
(SIGN) comparing gefitanib with docetaxel as second line therapy in patients
with advanced (stage IIIb or IV) non small cell cancer. Proc ASCO 2005;23:16S.
9
26. Vrdoljak E., Petrić Miše B. Protokol za adjuvantno sustavno liječenje raka dojke
u vrlo mladih žena. Zbornik radova 17. Znanstvenog sastanka o bolestima
dojke. 2007; 225-238.
31. Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A,
Coombes C, Bliss JM, Kilburn LS. Reversal of skeletal effects of endocrine
treatments in the intergroup exemestane study. Breast Cancer 2008;Abstract No
1128.
10
38. Vrdoljak E, Berić Jozić G, Bošković L, Ban M. Perspektive sustavnog liječenja
raka dojke – individualizirana ciljana terapija. Zbornik radova 20. Znanstvenog
sastanka o bolestima dojke. 2010;35-48.
42. E. Vrdoljak, M. Ban. Jesu li nam potrebni centri za rak dojke kao središta
izvrsnosti za dijagnostiku i liječenje. Zbornik radova 21. Znanstvenog sastanka o
bolestima dojke. 2011;43-51.
43. E. Vrdoljak, J. Viculin. Moderni pristup u liječenju sindroma zloćudnog umora kod
onkoloških bolensika. Knjiga sažetaka IV. hrvatskog kongresa Potporno liječenje
onkoloških bolesnika; 2011; 16:18
Organizacija tečajeva:
11
1. Inicijator i tajnik organizacije tečaja trajne izobrazbe liječnika primarne
zdravstvene zaštite iz područja onkologije. Isti je održan 1994. godine s velikim
uspjehom. Prijavljeno je bilo 105 liječnika.
12
4. Evaluation of clinical efficacy of TTS-fentanyl in strong opioid naive and strong
opioid pre-treated adult patients with cancer releated pain without stabilization
phase: An open multicentre study. Janssen Cillag sponsored trial.
12. A phase II study of first line weekly Taxol plus herceptin followed by weekly
herceptin in women with locally advanced or metastatic breast cancer and
HER2 overexpression
13. A phase II, Open Label, Randomized, Comparative Study of Exemastan versus
Anastrazole in Post-menopausal Breast Cancer Subjects with Visceral Disease
13
15. A phase III, randomized, open-label study of IV Edotecarin vs Temozolomide or
Carmustine (BCNU) or Lomustine (CCNU) in patients with glioblastoma
multiforme that has progressed/recurred after alkylator-based (neo)adjuvant
chemotherapy
18. A multicenter phase III randomised trial comparing Docetaxel (Taxotere) and
Trastuzumab (Herceptin) with Docetaxel (Taxotere), Carboplatin and
Trastuzumab (Herceptin) as first line chemotherapy for patients with advanced
breast cancer containing HER2 gene amplification.
20. A multicenter phase III randomized trial comparing Docetaxel (Taxotere) and
Trastuzumab (Herceptin) with Docetaxel (Taxotere), Carboplatin and
Trastuzumab (Herceptin) as first line chemotherapy for patient with advanced
breast cancer containing HER2 gene amplification.
24. A Phase III Trial Of Novel Epothilone BMS-247550 Plus Capecitabine Versus
Capecitabine Alone In Patients With Advanced Breast Cancer Previously
Treated With An Anthracycline And A Taxane
14
25. A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of
E7389 versus “Treatment of Physician's Choice” in Patients with Locally
Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two
and Maximum of Five Prior Chemotherapy Regiments, Including an
Anthracycline and a Taxane
27. A SU011248 Expanded Access Protocol for Therapy of Patients with Metastatic
Renal Cell Carcinoma who are Ineligible for Participation in other SU011248
Protocols but may Derive Benefit from Treatment with SU011248
28. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with
HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer
Comparing Chemoterapy Plus Trastuzumab with Chemoterapy Plus
Trastuzumab Plus Bevacizumab
15